ADAPTED POSTERS

Titles of posters presented by ADAPTED researchers. For more information please contact the ADAPTED Project office at adapted@modus.ltd.

Candidates genes and pathways from ADAPTED Stage I integrative analysis

Presented by: Laura Madrid (CAEBi)

Conference: IMI 10th Anniversary Scientific Symposium

TMT-based comparison of ApoE ε4 and ε3 mouse brain samples – proteomics insights into the aetiology of Alzheimer’s disease

Presented by: Armel Nicolas (DCB) 

Conference: The Austrian Metabolomics and Proteomics Conference 2018 

Looking for therapeutic entry points for Alzheimer’s disease: lessons learned from agnostic trans-co-regulatory network analyses of APOE, TREM2, PLCG2 and ABI3 loci

Presented by: Agustín Ruiz (FACE) 

Conference: The Alzheimer's Association International Conference (AAIC) 2018, Chicago, Illinios, USA.  

Systematic APOE genotype-stratified analysis of human omics data - a study from the IMI ADAPTED project

Presented by: Margaretha Bakker (Abbvie)

Conference: The Alzheimer's Association International Conference (AAIC) 2018, Chicago, Illinios, USA.  

APOE-ε4 modulates levels of ω-3 and ω-6 fatty acids in Alzheimer’s disease dementia

Presented by: Holger Wagner (UKB),  Alfredo Ramirez (UKB).

 

Conference: The Alzheimer's Association International Conference (AAIC) 2018, Chicago, Illinios, USA.  

Modeling Alzheimer’s disease pathophysiology using isogenic human APOE iPSC-derived neural cells

Presented by: Lamiaa Bahnassawy (AbbVie) 

 

Conference: ISSCR Annual Meeting 2018, Melbourne, Australia 

Cerebrospinal fluid and plasma levels of Lysophosphatidic acids (LPAs) associate with cerebrospinal fluid Aβ-42 and P-tau

Presented by:  Shahzad Ahmad (EMC)

Conference: 2nd Meeting of Society of CSF analysis and clinical neurochemistry, Amsterdam, NL. 

Please reload

©2018 ADAPTED

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115975. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations